Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.50 |
| ▸ | CNR1 | P21554 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381942 | 0.97 | CNR2 (0.51) | CNR2CNR1ALDH1A1HSD17B10POLB | |
| SCHEMBL3916177 | 0.90 | CNR2 (0.58) | CNR2CNR1 | |
| SCHEMBL3920939 | 0.90 | CNR2 (0.44) | CNR2CNR1ALDH1A1HSD17B10POLB | |
| SCHEMBL3989553 | 0.84 | CNR2 (0.47) | CNR2CNR1POLB | |
| SCHEMBL3918429 | 0.84 | CNR2 (0.52) | CNR2CNR1ALDH1A1HSD17B10NPC1 | |
| SCHEMBL3995310 | 0.83 | CNR2 (0.51) | CNR2CNR1POLB | |
| SCHEMBL4385562 | 0.82 | CNR2 (0.52) | CNR2CNR1NPC1 | |
| SCHEMBL4384382 | 0.82 | CNR2 (0.43) | CNR2CNR1NPC1 | |
| SCHEMBL4392439 | 0.82 | CNR2 (0.56) | CNR2CNR1NPC1 | |
| SCHEMBL4382324 | 0.81 | CNR2 (0.74) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | claimed |
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | TRPV1, CNR1, CNR2 | CNR2 3/4885CNR1 2/4885ALDH1A1 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.